US 11,884,730 B2
Methods of sensitizing cancer to immunotherapy
Alex Yee-Chen Huang, Cleveland, OH (US); and Agne Petrosiute, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on Sep. 21, 2021, as Appl. No. 17/480,831.
Application 17/480,831 is a continuation of application No. 16/303,846, granted, now 11,124,571, previously published as PCT/US2017/034285, filed on May 24, 2017.
Claims priority of provisional application 62/432,131, filed on Dec. 9, 2016.
Claims priority of provisional application 62/341,459, filed on May 25, 2016.
Prior Publication US 2022/0169735 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C12N 9/12 (2006.01); C07K 14/705 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 39/39541 (2013.01); A61P 35/00 (2018.01); C07K 14/70596 (2013.01); C12N 9/12 (2013.01); C12Y 207/11022 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method of inhibiting Interferon-y (IFN-y) induced Programmed Death-Ligand 1 (PD-L1) expression in medulloblastoma or rhabdomyosarcoma cancer cells of a subject, the method comprising:
detecting the expression level of Cdk5 in the medulloblastoma or rhabdomyosarcoma cancer cells prior to administration of the Cdk5 inhibitor;
comparing the detected expression level of Cdk5 to a threshold level; and
administering to IFN-y induced PD-L1 overexpressing cancer cells of the subject an amount of a CdK5 inhibitor effective to suppress immune checkpoint PD-L1 expression in the medulloblastoma or rhabdomyosarcoma cancer cells and to enhance an immune response to the medulloblastoma or rhabdomyosarcoma cancer cells if the detected expression level of Cdk5 exceeds the threshold level.